Vatelizumab is an immunomodulator. It binds to integrin alpha 2.[1]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | integrin alpha 2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.[2]
References
edit- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- ^ Mozaffari S, Nikfar S, Abdollahi M (2015). "Inflammatory bowel disease therapies discontinued between 2009 and 2014". Expert Opin Investig Drugs. 24 (7): 949–56. doi:10.1517/13543784.2015.1035432. PMID 25861835. S2CID 26104155.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |